Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by leveraging its proprietary Cas12a chRDNA (CRISPR hybrid RNA-DNA) genome-editing technology. The company is advancing a pipeline of wholly-owned, genome-edited, allogeneic CAR-T and CAR-NK cell therapies for the treatment of hematologic malignancies and solid tumors. Caribou's approach aims to develop 'off-the-shelf' cell therapies with enhanced anti-tumor activity and improved persistence.
The headquarters serves as the primary center for Caribou's research and development, clinical operations, manufacturing process development, and corporate functions.
Located in the vibrant San Francisco Bay Area biotech hub, the facility houses state-of-the-art laboratories for CRISPR gene editing, cell line engineering, process development, and analytical characterization of cell therapies.
Caribou fosters a collaborative, innovative, and science-driven work environment. The culture emphasizes scientific excellence, teamwork, and a shared commitment to developing novel therapies for patients with unmet medical needs.
The Berkeley headquarters is central to Caribou's operations, enabling the discovery, development, and advancement of its pipeline of next-generation allogeneic cell therapies.
While Caribou Biosciences is headquartered and primarily operates from its Berkeley, California facility, its focus on developing therapies for globally prevalent diseases like cancer means its research, clinical trials, and potential future commercialization efforts have international implications. The company may engage in collaborations or partnerships that extend its reach and impact worldwide, and its clinical trials often involve sites in multiple regions to ensure diverse patient participation.
2929 7th Street, Suite 105
Berkeley
CA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Caribou Biosciences' leadership includes:
Caribou Biosciences has been backed by several prominent investors over the years, including:
In the past 12 months, Caribou Biosciences has strengthened its executive team with key appointments, notably a new Chief Business Officer and a new Chief Operating Officer, to support its expanding clinical programs and operational capabilities. No high-profile executive departures were publicly announced during this period.
Discover the tools Caribou Biosciences uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Caribou Biosciences commonly uses the [first].[last]@cariboubio.com email format for its employees. While this is the most prevalent structure, other variations like [first_initial][last]@cariboubio.com might occasionally be used.
[first].[last]@cariboubio.com
Format
jane.doe@cariboubio.com
Example
75%
Success rate
Caribou Biosciences / GlobeNewswire • May 9, 2024
Caribou reported a net loss of $33.7 million for Q1 2024 and ended the quarter with $306.9 million in cash, cash equivalents, and marketable securities. The company highlighted progress in its CB-010 ANTLER trial, plans for initial data from its CB-011 CaMMouflage trial in H2 2024, and recent IND clearance for CB-012 in r/r AML....more
Caribou Biosciences / GlobeNewswire • April 2, 2024
Caribou announced its presentation of preclinical data for CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia (r/r AML). The data showcased CB-012's enhanced anti-tumor activity due to its immune-cloaking strategy with a B2M knockout and B2M–HLA-E transgene insertion....more
Caribou Biosciences / GlobeNewswire • February 28, 2024
Caribou announced that the U.S. Food and Drug Administration (FDA) cleared its IND application for CB-012, its lead allogeneic CAR-T cell therapy candidate from its Cas12a chRDNA-edited CAR-T cell platform for treating r/r AML. A Phase 1 clinical trial is planned for mid-2024....more
Caribou Biosciences / GlobeNewswire • December 11, 2023
Caribou presented updated results from its ANTLER Phase 1 trial for CB-010 in r/r B-NHL at the 65th ASH Annual Meeting. The data showed a 100% overall response rate and a 79% complete response rate (CR) at the initial dose level among 14 evaluable patients, with a 43% CR rate at 6 months....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Caribou Biosciences, are just a search away.